RxDoctor Payments Data

Jololene Allan

Family · South Jordan, UTNPI 1316017627

Payments from drug & device makers

$2,700in general payments, 2019–2025

Across 146 payments — averaging $18.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$202
  • Astellas Pharma US Inc$167
  • AstraZeneca$153
  • Highridge Medical LLC$126
  • Axsome Therapeutics, Inc.$102
  • plus $675 from 18 others

What the payments were for

  • Food & beverage$2,60797%
  • Education$933%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,700 in reported general payments places this provider in the 85th percentile of 1,460 family providers in Utah.

See all family providers in Utah

Medicare billing

Part B allowed, 2024
$9,172
Medicare patients
46
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl35$49,221
FarxigaDapagliflozin Propanediol41$35,595
MounjaroTirzepatide24$31,566
Breztri AerosphereBudesonide/Glycopyr/Formoterol39$25,200
OzempicSemaglutide11$20,615
EliquisApixaban22$20,042
JardianceEmpagliflozin19$18,285
JanuviaSitagliptin Phosphate17$13,926
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog24$11,522
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$11,520
XareltoRivaroxaban12$6,413
Oxycodone Hcl121$3,810
Lurasidone Hcl13$3,086
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,451
Ventolin HfaAlbuterol Sulfate39$2,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$153$60,79580 claims
AbbVieVraylar$1,274$49,22135 claims
Lilly USA, LLCMounjaro$202$31,56624 claims
Novo NordiskOzempic$98$20,61511 claims
PfizerEliquis$14$20,04222 claims
Boehringer IngelheimJardiance$16$18,28519 claims
GSKTrelegy Ellipta$16$11,52020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,460 family providers in Utah.

Other family in South Jordan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →